{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"71","value":"0"},{"groupId":"OG001","lowerLimit":"24","upperLimit":"91","value":"63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Overall response rate is defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity.","id":"OG000","title":"Brentuximab Vedotin 1.4 mg/kg: Phase 1"},{"description":"Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle starting from Cycle 2 until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG001","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population included participants who received at least 1 dose of study drug, have measurable disease at baseline, and 1 postbaseline disease assessment. Participants enrolled in Phase 1 of the study were evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT (Up to 15 months)","title":"Overall Response Rate (ORR) (Phase 1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}